Check-CapCHEK
CHEK
About: Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
Employees: 85
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.74% less ownership
Funds ownership: 2.33% [Q4 2024] → 1.59% (-0.74%) [Q1 2025]
13% less funds holding
Funds holding: 16 [Q4 2024] → 14 (-2) [Q1 2025]
46% less capital invested
Capital invested by funds: $134K [Q4 2024] → $72.4K (-$61.9K) [Q1 2025]
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Research analyst outlook
We haven’t received any recent analyst ratings for CHEK.
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders
Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting TORONTO , May 14, 2025 /PRNewswire/ -- Apollo Technology Capital Corporation ("Apollo Capital"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs", or the "Company"), owning approximately 3.0% of the Company's common stock, today posed several critical questions that shareholders should ask MediPharm management on this morning's conference call following its first quarter 2025 earnings report. CEO David Pidduck and his management team have not held a call with shareholders since the second quarter of 2024 to avoid having to defend themselves after destroying 99% of the value of the company's stock, or nearly $1 billion.
Neutral
PRNewsWire
1 month ago
MediPharm Labs Files Proxy Materials, Issues Chair's Letter to Shareholders
TORONTO , May 13, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, has filed its Management Information Circular ("MIC" or the "Circular") and proxy materials (the "Meeting Materials") for its upcoming Annual and Special Meeting of Shareholders, scheduled for June 16, 2025. The Meeting Materials will be sent to shareholders in the coming days, and are available on the SEDAR+ website at www.sedarplus.ca.
Neutral
PRNewsWire
1 month ago
Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction
Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Letter to MediPharm Shareholders and Files Proxy Circular TORONTO, ON , May 8, 2025 /PRNewswire/ -- Apollo Technology Capital Corporation ("Apollo"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs", or the "Company"), owning approximately 3.0% of the Company's common stock, today filed a dissident information proxy circular (the "Circular") in connection with its intention to nominate six highly qualified director candidates to MediPharm's Board of Directors (the "Board") at the Company's upcoming 2025 Annual and Special Meeting of Shareholders to be held on June 10, 2025 (the "Annual Meeting").
Positive
InvestorPlace
1 year ago
Why Is Check-Cap (CHEK) Stock Up 44% Today?
Check-Cap (NASDAQ: CHEK ) stock is on the rise Tuesday as the clinical stage medical diagnostics company announces a business combination with Nobul AI . This deal will have Check-Cap hand of the reigns of the company to Nobul AI's leadership team and shareholders.
Neutral
PRNewsWire
1 year ago
Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement
Proposed business combination to create a North American technology company with an AI-driven fintech marketplace. Combined company to apply for listing on Nasdaq and TSX TORONTO , March 25, 2024 /PRNewswire/ -- Nobul AI Corp. ("Nobul") and Check-Cap Ltd.
Neutral
PRNewsWire
1 year ago
SYMETRYX COMMENTS ON SUCCESSFUL CAMPAIGN AT CHECK-CAP LTD
TORONTO , Dec. 22, 2023 /PRNewswire/ - Symetryx Corporation ("Symetryx"), a Canadian venture company, is pleased to announce that the shareholders of Check-Cap Ltd. (NASDAQ: CHEK) voted overwhelmingly to elect all the director nominees proposed by Symetryx at the Annual General Meeting held on December 18 th 2023.
Neutral
PRNewsWire
1 year ago
CHECK- CAP BOARD MEMBER'S STATEMENT ON THE STAND SUGGESTS A POTENTIAL CONFLICT OF INTEREST WITH KEYSTONE DENTAL
SYMETRYX RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER SYMETRYX RECOMMENDS VOTING FOR THEIR QUALIFIED INDEPENDENT BOARD NOMINEES TIME IS SHORT - THE VOTE DEADLINE IS 11:59 pm EST THURSDAY DECEMBER 14 th 2023 - SHAREHOLDERS MAY VOTE OR CHANGE A PREVIOUSLY CAST VOTE UNTIL THAT TIME TORONTO , Dec. 13, 2023 /PRNewswire/ - Further to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) shareholders to VOTE AGAINST the Keystone Dental and FOR the Symetryx slate of highly qualified and independent director nominees.
Neutral
PRNewsWire
1 year ago
CITING THE MANY FDA ADVERSE EFFECTS TO KEYSTONE DENTAL - CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER ALSO RECOMMENDS VOTING FOR THE SYMETRYX BOARD NOMINEES
TORONTO , Dec. 8, 2023 /PRNewswire/ - Further to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) shareholders to VOTE AGAINST the Keystone Dental and FOR the Symetryx slate of highly qualified and independent director nominees.
Neutral
PRNewsWire
1 year ago
CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER AND FOR THE SYMETRYX BOARD OF DIRECTORS NOMINEES
TORONTO , Dec. 5, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") once again encourages our fellow shareholders of Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) to review the news release issued by Yoav Kimchy, PhD, the Founder and former Chief Technology Officer, and shareholder, of Check-Cap, who has stated in an open letter to his fellow shareholders that the value of the Intellectual Property of Check-Cap was, in essence, disregarded and assigned no monetary value when valuing the Keystone Dental transaction.
Neutral
PRNewsWire
1 year ago
Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting
Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO , Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ: CHEK) shares, today issued the following open letter to shareholders.
Charts implemented using Lightweight Charts™